SCA
CRSP icon

Spearhead Capital Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Spearhead Capital Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,226
Closed -$249K – 180
2021
Q3 		$249K Sell
2,226
-84
-4% -$10.6K 0.03% 175
2021
Q2 		$374K Sell
2,310
-1,396
-38% -$170K 0.05% 155
2021
Q1 		$452K Buy
3,706
+170
+5% +$25.7K 0.07% 89
2020
Q4 		$541K Sell
3,536
-601
-15% -$71K 0.09% 93
2020
Q3 		$346K Sell
4,137
-6
-0.1% -$532 0.07% 111
2020
Q2 		$304K Buy
+4,143
New +$242K 0.06% 104

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Spearhead Capital Advisors's CRSP Position: Q4 2021 in Review

Spearhead Capital Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 2,226 shares — an estimated $249K sold.

Spearhead Capital Advisors first reported a position in CRSP in Q2 2020 and held it in 6 quarters. The position peaked at $541K in Q4 2020. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Spearhead Capital Advisors reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Spearhead Capital Advisors sold 2,226 CRISPR Therapeutics shares in Q4 2021, an estimated $249K.
  • Spearhead Capital Advisors first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 6 quarters.
  • Spearhead Capital Advisors's CRISPR Therapeutics position peaked at $541K in Q4 2020.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Spearhead Capital Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.